Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel
about
In Vivo and in Vitro Proteome Analysis of Human Immunodeficiency Virus (HIV)-1-infected, Human CD4+ T Cells.A Conversation Among the IAS-USA Board of Directors: Hot Topics and Emerging Data in HIV Research and Care.Factors associated with pre-treatment HIV RNA: application for the use of abacavir and rilpivirine as the first-line regimen for HIV-infected patients in resource-limited settings.Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed AdultsWhen could new antiretrovirals be recommended for national treatment programmes in low-income and middle-income countries: results of a WHO Think Tank.Novel approaches to HIV therapy.Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment.Comparative effectiveness of tenofovir in HIV-infected treatment-experienced patients: systematic review and meta-analysis.Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome.Validating a self-report measure of HIV viral suppression: an analysis of linked questionnaire and clinical data from the Canadian HIV Women's Sexual and Reproductive Health Cohort Study.Development and validation of reversed-phase HPLC gradient method for the estimation of efavirenz in plasma.Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide.Post-treatment control or treated controllers? Viral remission in treated and untreated primary HIV infection.Drug interactions between hormonal contraceptives and antiretrovirals.Trimeric gp120-specific bovine monoclonal antibodies require cysteine and aromatic residues in CDRH3 for high affinity binding to HIV Env.Liver stiffness is not associated with short- and long-term plasma HIV RNA replication in immunocompetent patients with HIV infection and with HIV/HCV coinfection.Pregnancy incidence and intention after HIV diagnosis among women living with HIV in Canada.HIV in the dialysis population: Current issues and future directions.Inhibitory Effects of Selected Antituberculosis Drugs on Common Human Hepatic Cytochrome P450 and UDP-glucuronosyltransferase Enzymes.Multimethod Longitudinal HIV Drug Resistance Analysis in Antiretroviral-Therapy-Naive Patients.HIV Treatment and Prevention: An Overview of Recommendations From the IAS-USA Antiretroviral Guidelines Panel.Initiating HCV treatment with direct acting agents in opioid agonist treatment: When to start for people co-infected with HIV?Insight into the ERVK Integrase - Propensity for DNA Damage.Pharmacogenetic considerations in the treatment of HIV.Patterns of transmitted drug resistance and virological response to first-line antiretroviral treatment among HIV-positive people who use illicit drugs in a Canadian setting.Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients.Mining for pairs: shared clinic visit dates identify steady HIV-positive partnerships.An update on the Barriers to Adherence and a Definition of Self-Report Non-adherence Given Advancements in Antiretroviral Therapy (ART).Tolerability of integrase inhibitors in a real-life setting.Acute Care Management of the HIV-Infected Patient: A Report from the HIV Practice and Research Network of the American College of Clinical Pharmacy.HIV Prevention: Opportunities and Challenges.Emtricitabine + tenofovir alafenamide for the treatment of HIV.Longitudinal HIV Care Trajectories in North Carolina.Nuclear landscape of HIV-1 infection and integration.Advances in therapy for the prevention of HIV transmission from mother to child.Effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen for the treatment of HIV-1 infection in naive patients.The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions.Nucleoside reverse transcriptase inhibitor-reducing strategies in HIV treatment: assessing the evidence.An HIV-positive Case of Obstructive Jaundice Caused by Immune Reconstitution Inflammatory Syndrome of Tuberculous Lymphadenitis Successfully Treated with Corticosteroids.
P2860
Q30398955-3358C38F-B805-4894-9B51-FCFC74334CEFQ31162537-0CCCE9D3-D77E-4EFF-93CC-A78C2B92CD0FQ33644568-2BF426CE-3F80-4536-A908-51CCA79A9002Q33669829-9973AC68-822C-4751-828A-B309420A4882Q33765196-7DB6BD7D-C251-4DC9-9775-6964AC9B0350Q33777819-B9DF5057-86A0-4BFC-892F-C27F212C0AB1Q33880782-0E8E42E2-927C-4439-9A68-8A85A534A21FQ36220644-48DC299E-4577-4ED8-A667-8A839EA51D9DQ36284159-ACA1D4BE-F3A7-4AD0-AC46-02A35BCF766FQ36322539-14207FE7-2FC8-415E-B1C1-E1C9E04870EBQ36372039-67C736CD-F25B-42E3-A1CF-762A7649C87EQ37582471-230CE416-F444-458B-A69D-CEFF6DDC5E84Q37604553-E0033DBE-61F0-4708-9B99-B760DCFA66ACQ37613230-ED9C67FC-BFD2-4422-A7F9-35A501B01C8FQ37735345-6CF67EA5-ABCB-490B-A17C-DDC00AB3CB7DQ37742119-65578ED9-08C9-439C-8030-66A7B6E202C5Q38606313-71B3B14C-D21F-46A4-9A46-FDE05E7EE548Q38670050-3DB46578-02A4-452A-B08A-E5E9751D1258Q38671530-6DC0D820-E3CE-41C5-B856-78333C50960DQ38701604-CB1B81C8-D616-4A87-9CC1-F0645EF74E43Q38703935-E5860B7E-5F94-41E7-AF76-91ADDD3F91F9Q38731295-F541279A-2B10-4576-9552-69E8FBC1E287Q38746105-50ABA59E-F184-4F81-8AE9-25C7AB2CE28AQ38781083-ADCDC064-5AAA-42AB-9153-F08BCB99C978Q38782609-CCA0165D-2A76-48B4-86BF-0619A0A12830Q38798050-12033267-8753-4E96-87E8-CA20463A0899Q38802093-6657DE05-0FCD-4DCC-8C08-04E7F06E1743Q38853942-D4F5CCD1-C318-4F01-94E3-7E3245935D46Q38869783-6713D59C-B5DB-483C-81FD-40A3A2DFCA13Q38883840-C460C03A-6EA5-453A-8523-30F77A869281Q38920747-917A10D3-5258-4C82-9D95-9C9AB171311DQ38957187-82EF792B-5572-4381-8D01-AF32A0F757ECQ38984695-F7B47B62-6A5B-48E7-8BFB-F1D51C8CA5F6Q39024983-39B7191E-E9E4-4CD1-90AC-8F6DACD22440Q39035944-F38BCF2D-F9B2-4283-B0BF-195F23DAC7A3Q39234019-0D79265A-79EB-439B-AC2D-8DAAC11CC201Q39426047-6567AD43-68AC-4DAC-9064-79D7B0EBBC80Q39427540-4D457B6E-337D-45AC-85C8-6D010E8E9E0CQ39453985-6AA32447-FEF7-4413-89B5-235BE8C99837Q40040109-A112E557-292A-4960-95D8-C9C2C7A4B852
P2860
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antiretroviral Drugs for Treat ...... al Antiviral Society-USA Panel
@en
Antiretroviral Drugs for Treat ...... l Antiviral Society-USA Panel.
@nl
type
label
Antiretroviral Drugs for Treat ...... al Antiviral Society-USA Panel
@en
Antiretroviral Drugs for Treat ...... l Antiviral Society-USA Panel.
@nl
prefLabel
Antiretroviral Drugs for Treat ...... al Antiviral Society-USA Panel
@en
Antiretroviral Drugs for Treat ...... l Antiviral Society-USA Panel.
@nl
P2093
P2860
P50
P921
P356
P1476
Antiretroviral Drugs for Treat ...... al Antiviral Society-USA Panel
@en
P2093
Carlos del Rio
Constance A Benson
Donna M Jacobsen
Joel E Gallant
Melanie A Thompson
Michael J Mugavero
Michael S Saag
Paul A Volberding
Paul E Sax
Rajesh T Gandhi
P2860
P304
P356
10.1001/JAMA.2016.8900
P407
P577
2016-07-01T00:00:00Z